/CVAC
CVAC Stock - CureVac N.V.
Healthcare|BiotechnologyNASDAQ
$4.16-2.80%
$0.12 (-2.80%) • Dec 19
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.23
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).90
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.49
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+20.2%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CVAC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.12 – $4.20
TARGET (TP)$5.00
STOP LOSS$3.83
RISK/REWARD1:2.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.77
52W High$5.72
52W Low$2.48
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $535.18M | $53.76M | $67.42M | $102.99M | $48.90M |
| Gross Profit | $429.35M | $-70,608,000 | $-116,573,000 | $-135,205,000 | $34.73M |
| Gross Margin | 80.2% | -131.3% | -172.9% | -131.3% | 71.0% |
| Operating Income | $177.68M | $-274,207,000 | $-249,457,000 | $-412,263,000 | $-124,002,000 |
| Net Income | $162.19M | $-260,167,000 | $-249,029,000 | $-411,716,000 | $-129,074,000 |
| Net Margin | 30.3% | -484.0% | -369.4% | -399.8% | -264.0% |
| EPS | $0.72 | $-1.18 | $-1.32 | $-2.21 | $-0.98 |
Company Overview
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$12
Average Target
↑ 193.3% Upside
Now
$4
Low
$12
Average
$21
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 13th 2025 | Jefferies | Downgrade | Hold | $5 |
| April 25th 2024 | Leerink Partners | Downgrade | Market Perform | $4← $12 |
| June 8th 2023 | SVB Securities | Initiation | Outperform | $13 |
| January 19th 2023 | UBS | Upgrade | Buy | $18← $8 |
| January 9th 2023 | Jefferies | Upgrade | Buy | $21← $9 |
Earnings History & Surprises
CVACBeat Rate
38%
Last 16 quarters
Avg Surprise
+48.2%
EPS vs Estimate
Beats / Misses
6/9
1 met exactly
Latest EPS
$-0.10
Q4 2025
EPS Surprise History
Q2 24
-54.5%
$-0.34vs$-0.22
Q3 24
-21.4%
$-0.34vs$-0.28
Q4 24
+146.3%
$1.65vs$0.67
Q2 25
+31.8%
$-0.15vs$-0.22
Q2 25
-50.0%
$-0.24vs$-0.16
Q3 25
-66.7%
$-0.30vs$-0.18
Q4 25
+1070.6%
$1.65vs$-0.17
Q4 25
-21.7%
$-0.10vs$-0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 9, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 24, 2025 | $-0.08 | $-0.10 | -21.7% | ✗ MISS |
Q4 2025 | Nov 11, 2025 | $-0.17 | $1.65 | +1070.6% | ✓ BEAT |
Q3 2025 | Aug 15, 2025 | $-0.18 | $-0.30 | -66.7% | ✗ MISS |
Q2 2025 | May 20, 2025 | $-0.16 | $-0.24 | -50.0% | ✗ MISS |
Q2 2025 | Apr 10, 2025 | $-0.22 | $-0.15 | +31.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $0.67 | $1.65 | +146.3% | ✓ BEAT |
Q3 2024 | Aug 15, 2024 | $-0.28 | $-0.34 | -21.4% | ✗ MISS |
Q2 2024 | May 23, 2024 | $-0.22 | $-0.34 | -54.5% | ✗ MISS |
Q2 2024 | Apr 24, 2024 | $-0.22 | $-0.42 | -91.3% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.26 | $-0.24 | +7.7% | ✓ BEAT |
Q3 2023 | Aug 17, 2023 | $-0.28 | $-0.33 | -17.9% | ✗ MISS |
Q2 2023 | May 30, 2023 | $-0.29 | $-0.29 | 0.0% | = MET |
Q2 2023 | Apr 27, 2023 | $-0.22 | $-0.71 | -223.4% | ✗ MISS |
Q4 2022 | Nov 16, 2022 | $-0.27 | $-0.25 | +6.5% | ✓ BEAT |
Q3 2022 | Aug 18, 2022 | $-0.26 | $-0.33 | -25.8% | ✗ MISS |
Q2 2022 | May 25, 2022 | $-0.50 | $-0.09 | +81.9% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | — | $-0.01 | — | — |
Q4 2021 | Nov 18, 2021 | — | $-0.93 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.00 | — | — |
Latest News
BioNTech Minimum Condition in CureVac Exchange Offer Has Been Satisfied
📈 PositiveBenzinga•Dec 3, 2025, 02:04 PM•Also:
CureVac Q3 EPS $1.41 Beats $(0.17) Estimate, Sales $63.295M Beat $14.520M Estimate
📈 PositiveBenzinga•Nov 24, 2025, 01:18 PM
BioNTech Commences Public Exchange Offer For All Outstanding Shares Of CureVac; CureVac Shareholders Receive ~$5.46 In BioNTech ADSs For Each CureVac Share
📈 PositiveBenzinga•Oct 22, 2025, 10:51 AM•Also:
BioNTech to buy German rival CureVac for $1.25B in all-stock deal
📈 PositiveSeeking Alpha•Jun 12, 2025, 10:58 AM•Also:
Frequently Asked Questions about CVAC
What is CVAC's current stock price?
CureVac N.V. (CVAC) is currently trading at $4.16 per share. The stock has moved -2.80% today.
What is the analyst price target for CVAC?
The average analyst price target for CVAC is $5.00, based on 1 analyst.
What sector is CureVac N.V. in?
CureVac N.V. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CVAC's market cap?
CureVac N.V. has a market capitalization of $0.94 billion, making it a small-cap company.
Does CVAC pay dividends?
No, CureVac N.V. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.02
Mkt Cap: $1.0B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
INBX
Inhibrx Biosciences, Inc.
$86.13
Mkt Cap: $1.3B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
NVAX
Novavax, Inc.
$6.66
Mkt Cap: $1.1B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
TRML
Tourmaline Bio, Inc.
$47.98
Mkt Cap: $1.2B
Explore stocks similar to CVAC for comparison